HU9904549A - Vaccines - Google Patents
VaccinesInfo
- Publication number
- HU9904549A HU9904549A HU9904549A HUP9904549A HU9904549A HU 9904549 A HU9904549 A HU 9904549A HU 9904549 A HU9904549 A HU 9904549A HU P9904549 A HUP9904549 A HU P9904549A HU 9904549 A HU9904549 A HU 9904549A
- Authority
- HU
- Hungary
- Prior art keywords
- relates
- present
- formulations
- vaccines
- sapőnaria
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229930182558 Sterol Natural products 0.000 abstract 1
- 235000014787 Vitis vinifera Nutrition 0.000 abstract 1
- 240000006365 Vitis vinifera Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
- C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
A találmány új vakcinakészítményekre, előállításűkra szőlgálóeljárásőkra, valamint alkalmazásűkra vőnatkőzik. Közelebbről atalálmány tárgyát alűmőt (alűmíniűm-hidrőxidőt és/vagy alűmíniűm-főszfátőt) antigént, a Qűillaja Sapőnaria Mőlina fa kérgéből kivőnt,imműnőlógiailag aktív anyagőt, példáűl QS21-et, valamint szterinttartalmazó vakcinák képezik. ŕ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9620795.6A GB9620795D0 (en) | 1996-10-05 | 1996-10-05 | Vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
HU9904549A true HU9904549A (en) | 2000-05-28 |
HUP9904549A3 HUP9904549A3 (en) | 2001-06-28 |
Family
ID=10800990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9904549A HUP9904549A3 (en) | 1996-10-05 | 1997-09-30 | Vaccines |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0939650A1 (hu) |
JP (1) | JP2001501640A (hu) |
KR (1) | KR20000048866A (hu) |
CN (1) | CN1238696A (hu) |
AR (1) | AR009958A1 (hu) |
AU (1) | AU714930B2 (hu) |
BR (1) | BR9711853A (hu) |
CA (1) | CA2267191A1 (hu) |
CO (1) | CO4910170A1 (hu) |
CZ (1) | CZ116799A3 (hu) |
GB (1) | GB9620795D0 (hu) |
HU (1) | HUP9904549A3 (hu) |
IL (1) | IL128985A0 (hu) |
NO (1) | NO991524D0 (hu) |
NZ (1) | NZ334734A (hu) |
PL (1) | PL332633A1 (hu) |
TR (1) | TR199900729T2 (hu) |
WO (1) | WO1998015287A1 (hu) |
ZA (1) | ZA978868B (hu) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6864289B1 (en) | 1999-09-24 | 2005-03-08 | Nihon Nohyaku Co., Ltd. | Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2327693T3 (es) * | 1997-08-29 | 2009-11-02 | Antigenics Inc. | Composiciones que comprenden el adyvante qs-21 y polisorbato o ciclodextrina excipiente. |
GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
ATE357252T1 (de) | 1998-10-16 | 2007-04-15 | Glaxosmithkline Biolog Sa | Adjuvanzsysteme und impfstoffe |
AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
CZ303515B6 (cs) | 1999-04-19 | 2012-11-07 | Smithkline Beecham Biologicals S. A. | Adjuvantní prostredek |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
WO2001030847A1 (en) | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
NZ518999A (en) * | 1999-11-19 | 2002-12-20 | Csl Ltd | Vaccine compositions |
US6905712B2 (en) | 1999-12-08 | 2005-06-14 | Statens Veterinarmedicinska Anstalt | Vaccine adjuvants comprising ginseng plant extract and added aluminum salt |
WO2001041802A1 (en) * | 1999-12-08 | 2001-06-14 | Statens Veterinärmedicinska Anstalt | Vaccine adjuvants comprising ginseng plant extract and added aluminium salt |
AU5810201A (en) | 2000-05-10 | 2001-11-20 | Aventis Pasteur | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
PT1889630E (pt) | 2000-10-18 | 2012-02-29 | Glaxosmithkline Biolog Sa | Vacinas compreendendo o antigénio mage ligado a um fragmento da proteína d |
WO2002067983A1 (en) * | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Novel vaccine |
WO2002074336A2 (en) * | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
GB0123580D0 (en) * | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
JP2005533855A (ja) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | 病原性ウイルスからの別のリーディングフレームによりコードされる抗原 |
EP2402026A3 (en) | 2002-09-13 | 2012-04-18 | Intercell AG | Method for isolating hepatitis C virus peptides |
PL376792A1 (pl) | 2002-10-23 | 2006-01-09 | Glaxosmithkline Biologicals S.A. | Sposoby szczepienia przeciwko malarii |
JP2006521321A (ja) * | 2003-03-24 | 2006-09-21 | インターツェル・アクチェンゲゼルシャフト | 免疫応答を促進するためのミョウバンおよびTh1免疫応答誘起アジュバントの使用 |
ATE485056T1 (de) | 2003-03-24 | 2010-11-15 | Intercell Ag | Verbesserte impfstoffe |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
GB0519871D0 (en) | 2005-09-30 | 2005-11-09 | Secr Defence | Immunogenic agents |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
ES2420829T3 (es) | 2005-11-04 | 2013-08-27 | Novartis Vaccines And Diagnostics S.R.L. | Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular |
TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
AR058707A1 (es) | 2005-12-22 | 2008-02-20 | Glaxosmithkline Biolog Sa | Vacuna, procedimiento para fabricarla y su uso |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
JP2009531387A (ja) | 2006-03-30 | 2009-09-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
AU2007276219B2 (en) | 2006-07-18 | 2013-10-03 | Glaxosmithkline Biologicals S.A. | Vaccines for malaria |
US8323664B2 (en) | 2006-07-25 | 2012-12-04 | The Secretary Of State For Defence | Live vaccine strains of Francisella |
CA2669209C (en) * | 2006-11-20 | 2016-01-26 | Duecom Ab | Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
EP2137210B1 (en) | 2007-03-02 | 2016-10-19 | GlaxoSmithKline Biologicals SA | Novel method and compositions |
EA200901578A1 (ru) | 2007-06-26 | 2010-08-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae |
WO2009021931A1 (en) | 2007-08-13 | 2009-02-19 | Glaxosmithkline Biologicals S.A. | Vaccines |
EP3118213A1 (en) | 2007-12-19 | 2017-01-18 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Soluble forms of hendra and nipah virus f glycoprotein and uses thereof |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
GB0900455D0 (en) | 2009-01-13 | 2009-02-11 | Secr Defence | Vaccine |
GB0901411D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
GB0901423D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
CN102307590A (zh) | 2009-02-10 | 2012-01-04 | 诺华有限公司 | 具有减少量的角鲨烯的流感疫苗 |
AU2010220824A1 (en) * | 2009-03-05 | 2011-10-20 | Jenny Colleen Mccloskey | Treatment of infection |
GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
WO2011117408A1 (en) | 2010-03-26 | 2011-09-29 | Glaxosmithkline Biologicals S.A. | Hiv vaccine |
WO2012038801A1 (en) | 2010-09-21 | 2012-03-29 | National Institute Of Immunology | A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles |
BR112013004582A2 (pt) | 2010-09-27 | 2016-09-06 | Crucell Holland Bv | método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária |
CN103958544B (zh) | 2011-09-16 | 2018-04-24 | Ucb医药有限公司 | 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体 |
US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
WO2015092710A1 (en) | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
BR112019003462A2 (pt) | 2016-08-23 | 2019-06-25 | Glaxosmithkline Biologicals Sa | proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral |
GB201614799D0 (en) | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
WO2018104313A1 (en) * | 2016-12-07 | 2018-06-14 | Glaxosmithkline Biologicals Sa | Novel process |
GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
BR112019025193A2 (pt) * | 2017-05-30 | 2020-06-23 | Glaxosmithkline Biologicals S.A. | Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução |
GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
BR112020024285A2 (pt) | 2018-06-12 | 2021-03-02 | Glaxosmithkline Biologicals S.A. | polinucleotídeos e polipeptídeos de adenovírus |
WO2020030572A1 (en) | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
EP3897846A1 (en) | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
BR112021017584A2 (pt) | 2019-03-05 | 2021-11-09 | Glaxosmithkline Biologicals Sa | Regime e composições de imunização contra hepatite b |
US20230109193A1 (en) * | 2021-10-02 | 2023-04-06 | Massachusetts Institute Of Technology | Synergistic Combination of Alum and Non-Liposome, Non-Micelle Particle Vaccine Adjuvants |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
WO1993001831A1 (en) * | 1991-07-25 | 1993-02-04 | Idec Pharmaceuticals Corporation | Induction of cytotoxic t-lymphocyte responses |
PT692974E (pt) * | 1993-03-29 | 2003-09-30 | Pfizer | Vacinas clostridiais com multiplos componentes usando adjuvantes de saponina |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
-
1996
- 1996-10-05 GB GBGB9620795.6A patent/GB9620795D0/en active Pending
-
1997
- 1997-09-30 WO PCT/EP1997/005578 patent/WO1998015287A1/en not_active Application Discontinuation
- 1997-09-30 TR TR1999/00729T patent/TR199900729T2/xx unknown
- 1997-09-30 BR BR9711853A patent/BR9711853A/pt not_active Application Discontinuation
- 1997-09-30 CN CN97180166A patent/CN1238696A/zh active Pending
- 1997-09-30 JP JP10517196A patent/JP2001501640A/ja active Pending
- 1997-09-30 CA CA002267191A patent/CA2267191A1/en not_active Abandoned
- 1997-09-30 EP EP97910430A patent/EP0939650A1/en not_active Withdrawn
- 1997-09-30 PL PL97332633A patent/PL332633A1/xx unknown
- 1997-09-30 HU HU9904549A patent/HUP9904549A3/hu unknown
- 1997-09-30 AU AU47812/97A patent/AU714930B2/en not_active Ceased
- 1997-09-30 NZ NZ334734A patent/NZ334734A/xx unknown
- 1997-09-30 KR KR1019990702874A patent/KR20000048866A/ko not_active Application Discontinuation
- 1997-09-30 CZ CZ991167A patent/CZ116799A3/cs unknown
- 1997-09-30 IL IL12898597A patent/IL128985A0/xx unknown
- 1997-10-03 ZA ZA978868A patent/ZA978868B/xx unknown
- 1997-10-03 CO CO97057863A patent/CO4910170A1/es unknown
- 1997-10-03 AR ARP970104569A patent/AR009958A1/es unknown
-
1999
- 1999-03-29 NO NO991524A patent/NO991524D0/no not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6864289B1 (en) | 1999-09-24 | 2005-03-08 | Nihon Nohyaku Co., Ltd. | Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same |
Also Published As
Publication number | Publication date |
---|---|
CO4910170A1 (es) | 2000-04-24 |
CN1238696A (zh) | 1999-12-15 |
EP0939650A1 (en) | 1999-09-08 |
JP2001501640A (ja) | 2001-02-06 |
NZ334734A (en) | 2000-05-26 |
AU4781297A (en) | 1998-05-05 |
ZA978868B (en) | 1999-04-06 |
NO991524L (no) | 1999-03-29 |
NO991524D0 (no) | 1999-03-29 |
AR009958A1 (es) | 2000-05-17 |
CZ116799A3 (cs) | 1999-08-11 |
KR20000048866A (ko) | 2000-07-25 |
AU714930B2 (en) | 2000-01-13 |
PL332633A1 (en) | 1999-09-27 |
BR9711853A (pt) | 1999-08-24 |
TR199900729T2 (xx) | 1999-07-21 |
HUP9904549A3 (en) | 2001-06-28 |
IL128985A0 (en) | 2000-02-17 |
WO1998015287A1 (en) | 1998-04-16 |
GB9620795D0 (en) | 1996-11-20 |
CA2267191A1 (en) | 1998-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU9904549A (en) | Vaccines | |
ATE229978T1 (de) | Helicobacter proteine und impstoffe | |
EA199700272A1 (ru) | Вакцины, содержащие сапонин и стерин | |
BR9605153B1 (pt) | vacina de combinação, e, kit de vacinação. | |
DE60039198D1 (de) | Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen | |
WO2002009746A8 (en) | Vaccines comprising outer membrane vesciles from gram negative bacteria | |
NO20075902L (no) | Forbindelser for immunoterapi og diagnose av turberkolose og metoder for deres anvendelse | |
NO20015073D0 (no) | Vaksiner | |
ATE355375T1 (de) | Bakterioferritin aus helicobacter pylori | |
DK0792165T3 (da) | Immunogene præparater | |
ATE222930T1 (de) | Antigene arznei zur behandlung oder vorbeugung | |
DK1290160T3 (da) | Humane Pellino-polypeptider | |
ATE310008T1 (de) | Immunologische adjuvans verbindungen | |
BR0109164A (pt) | Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos | |
ATE193974T1 (de) | Chlamydia impfstoffen | |
BR0009077A (pt) | Antìgenos de tuberculose e métodos de uso dos mesmos | |
NO20020615L (no) | Vaksine | |
DK0975360T3 (da) | Bovint respiratorisk og enterisk coronavirus som vaccine | |
DE60239753D1 (de) | Impfstoff gegen infektiöses lachsanämievirus | |
DK0952771T3 (da) | Hidtil ukendte saponinpræparater og anvendelser deraf | |
ATE353226T1 (de) | Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form | |
DK0485463T3 (da) | Svækket hundeparvovirus (CPV), vaccine omfattende CPV og fremgangsmåde til forebyggelse af CPV-infektion i hunde | |
ITRM20010332A1 (it) | Vaccini a subunita' e procedimenti per la loro produzione. | |
RU96123912A (ru) | Способ иммунопрофилактики экспериментальной лепрозной инфекции | |
RU96116250A (ru) | Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней |